TY - JOUR
T1 - Effect of intravenous fluid volume on biomarkers of endothelial glycocalyx shedding and inflammation during initial resuscitation of sepsis
AU - The REFRESH Trial Investigators
AU - Macdonald, Stephen
AU - Bosio, Erika
AU - Keijzers, Gerben
AU - Burrows, Sally
AU - Hibbs, Moira
AU - O’Donoghue, Helen
AU - Taylor, David
AU - Mukherjee, Ashes
AU - Kinnear, Frances
AU - Smart, Lisa
AU - Ascencio-Lane, Juan Carlos
AU - Litton, Edward
AU - Fraser, John
AU - Shapiro, Nathan I.
AU - Arendts, Glenn
AU - Fatovich, Daniel
AU - McCutcheon, David
AU - Leonard, Anton
AU - Burcham, Jonathan
AU - Bellomo, Rinaldo
AU - Harley, Amanda
AU - Winearls, James
AU - Ascencio-Lane, Juan Carlos
AU - Brown, Simon
AU - Cooper, David
AU - Vlad, Ioana
AU - Wibrow, Bradley
AU - Anstey, Matthew
AU - Hazelwood, Sarah
N1 - Funding Information:
The REFRESH Trial was funded by the Emergency Medicine Foundation, Raine Medical Research Foundation and the Royal Perth Hospital Research Foundation. In-kind salary support from the Royal Perth Hospital Research Centre is gratefully acknowledged. SM is a Raine Foundation Clinician Research Fellow.
Funding Information:
Refresh trial investigators and participating hospitals: Armadale Health Service, WA (David McCutcheon, Ashes Mukherjee, Anton Leonard, Jonathan Burcham); Austin Health, VIC (David Taylor, Rinaldo Bellomo); Fiona Stanley Hospital, WA (Glenn Arendts, Edward Litton); Gold Coast University Hospital, QLD (Gerben Keijzers, Amanda Harley, James Winearls); Royal Hobart Hospital (Juan Carlos Ascencio-Lane, Simon Brown, David Cooper); Royal Perth Hospital, WA (Stephen Macdonald, Daniel Fatovich); Sir Charles Gairdner Hospital, WA (Ioana Vlad, Bradley Wibrow, Matthew Anstey); The Prince Charles Hospital, QLD (Frances Kinnear, John Fraser, Sarah Hazelwood). The study was endorsed by the Australasian College for Emergency Medicine Clinical Trials Group
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Purpose: To investigate the effect of IV fluid resuscitation on endothelial glycocalyx (EG) shedding and activation of the vascular endothelium and inflammation. Materials and methods: A planned biomarker sub-study of the REFRESH trial in which emergency department (ED) patients) with suspected sepsis and hypotension were randomised to a restricted fluid/early vasopressor regimen or IV fluid resuscitation with later vasopressors if required (usual care). Blood samples were collected at randomisation (T0) and at 3 h (T3), 6 h (T6)- and 24 h (T24) for measurement of a range of biomarkers if EG shedding, endothelial cell activation and inflammation. Results: Blood samples were obtained in 95 of 99 enrolled patients (46 usual care, 49 restricted fluid). Differences in the change in biomarker over time between the groups were observed for Hyaluronan (2.2-fold from T3 to T24, p = 0.03), SYN-4 (1.5-fold from T3 to T24, P = 0.01) and IL-6 (2.5-fold from T0 to T3, p = 0.03). No difference over time was observed between groups for the other biomarkers. Conclusions: A consistent signal across a range of biomarkers of EG shedding or of endothelial activation or inflammation was not demonstrated. This could be explained by pre-existing EG shedding or overlap between the fluid volumes administered in the two groups in this clinical trial. Trial registration Australia New Zealand Clinical Trials Registry ACTRN126160000006448 Registered 12 January 2016.
AB - Purpose: To investigate the effect of IV fluid resuscitation on endothelial glycocalyx (EG) shedding and activation of the vascular endothelium and inflammation. Materials and methods: A planned biomarker sub-study of the REFRESH trial in which emergency department (ED) patients) with suspected sepsis and hypotension were randomised to a restricted fluid/early vasopressor regimen or IV fluid resuscitation with later vasopressors if required (usual care). Blood samples were collected at randomisation (T0) and at 3 h (T3), 6 h (T6)- and 24 h (T24) for measurement of a range of biomarkers if EG shedding, endothelial cell activation and inflammation. Results: Blood samples were obtained in 95 of 99 enrolled patients (46 usual care, 49 restricted fluid). Differences in the change in biomarker over time between the groups were observed for Hyaluronan (2.2-fold from T3 to T24, p = 0.03), SYN-4 (1.5-fold from T3 to T24, P = 0.01) and IL-6 (2.5-fold from T0 to T3, p = 0.03). No difference over time was observed between groups for the other biomarkers. Conclusions: A consistent signal across a range of biomarkers of EG shedding or of endothelial activation or inflammation was not demonstrated. This could be explained by pre-existing EG shedding or overlap between the fluid volumes administered in the two groups in this clinical trial. Trial registration Australia New Zealand Clinical Trials Registry ACTRN126160000006448 Registered 12 January 2016.
KW - Endothelial glycocalyx
KW - Endothelium
KW - Fluid therapy
KW - Inflammation
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85153269519&partnerID=8YFLogxK
U2 - 10.1186/s40635-023-00508-4
DO - 10.1186/s40635-023-00508-4
M3 - Article
C2 - 37062769
AN - SCOPUS:85153269519
SN - 2197-425X
VL - 11
JO - Intensive Care Medicine Experimental
JF - Intensive Care Medicine Experimental
IS - 1
M1 - 21
ER -